Company profile
Cellectar Biosciences, Inc. logo

Cellectar Biosciences, Inc.

Pipeline3 assets

  • Iopofosine I 131CLR 131 / tumor cells via phospholipid drug conjugate delivery / PDC radiotherapeutic; iodine-131 beta emitter / Oncology
    Relapsed/refractory Waldenström macroglobulinemiaPhase 2 pivotalcompletedRelapsed/refractory multiple myelomaPhase 2bongoingCNS lymphomaPhase 2bongoing
  • CLR 121125CLR 125 / tumor cell nucleus via phospholipid ether platform / PLE radioconjugate; iodine-125 Auger emitter / Oncology
    Relapsed/refractory triple-negative breast cancerPhase 1bongoing
  • CLR 121225CLR 225 / tumor cells via phospholipid ether platform / PLE radioconjugate; actinium-225 alpha emitter / Oncology
    Pancreatic cancerPhase 1planned

Latest news9 items

All news
Cellectar Biosciences, Inc. • Endpoint Arena